Akeso's Cadonilimab Shows Promising Survival Benefit in Advanced Pancreatic Cancer Phase II Trial

Key Takeaways

• Cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, showed promising survival benefits in Phase II COMPASSION-26 trial for advanced pancreatic cancer
• The combination therapy represents a potential breakthrough for pancreatic ductal adenocarcinoma, a cancer type historically resistant to immunotherapy
• Results were presented at AACR 2026, positioning Akeso for potential Phase III development in a market with significant unmet medical need

---

Hong Kong-based Akeso Inc. (9926.HK) announced positive Phase II results for cadonilimab, its innovative PD-1/CTLA-4 bispecific antibody, showing promising survival benefits when combined with chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC).

The COMPASSION-26 study results, presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting on April 20, 2026, represent a potentially significant advancement in treating one of oncology’s most challenging cancers. The data cutoff occurred on October 20, 2025, though specific survival metrics were not disclosed in the initial announcement.

Revolutionary Bispecific Approach

Cadonilimab stands out as a first-in-class bispecific antibody that simultaneously targets both PD-1 and CTLA-4 immune checkpoints in a single molecule. This dual mechanism approach could offer advantages over current combination immunotherapies by providing more precise immune activation while potentially reducing toxicity compared to separate antibody combinations.

Pancreatic cancer remains one of the deadliest malignancies, with five-year survival rates below 10%. Current standard-of-care treatments like FOLFIRINOX and gemcitabine/nab-paclitaxel combinations provide modest survival benefits but come with significant toxicity profiles. Immunotherapy approaches, including pembrolizumab and nivolumab, have shown limited efficacy in pancreatic cancer compared to their success in other tumor types.

Market Impact and Competitive Landscape

The positive Phase II results position Akeso favorably in the competitive pancreatic cancer treatment landscape. If confirmed in Phase III trials, cadonilimab could capture significant market share in a therapeutic area with substantial unmet need. The global pancreatic cancer therapeutics market continues to grow as incidence rates increase and new treatment modalities emerge.

The bispecific antibody approach differentiates cadonilimab from existing checkpoint inhibitors and combination therapies. This mechanism could potentially overcome some of the immunosuppressive characteristics that make pancreatic tumors particularly resistant to single-agent immunotherapy.

Clinical Development Pathway

The encouraging Phase II data sets the stage for pivotal Phase III development, though Akeso has not yet announced specific timelines for advancing the program. Given the significant unmet need in pancreatic cancer, the company may explore accelerated regulatory pathways if survival benefits prove substantial and durable.

The COMPASSION-26 trial’s focus on first-line treatment positions cadonilimab to potentially become a new standard of care, competing directly with established chemotherapy regimens. Success in this indication could also support expansion into other solid tumor types where dual checkpoint inhibition might provide clinical benefit.

Investment and Partnership Implications

The positive trial results strengthen Akeso’s position for potential partnerships with larger pharmaceutical companies seeking to expand their oncology portfolios. The first-in-class nature of cadonilimab’s bispecific mechanism adds significant value proposition for global development and commercialization partnerships.

However, investors should note the inherent risks in pancreatic cancer drug development, where many promising early-stage results have failed to translate into meaningful clinical outcomes in larger trials. The historically poor response rates to immunotherapy in pancreatic cancer warrant cautious optimism pending full data disclosure and peer review.

---

Frequently Asked Questions

What makes cadonilimab different from existing pancreatic cancer treatments?

Cadonilimab is a first-in-class bispecific antibody that simultaneously targets both PD-1 and CTLA-4 immune checkpoints in a single molecule, potentially offering better immune activation with reduced toxicity compared to current combination therapies or chemotherapy regimens like FOLFIRINOX.

When will cadonilimab be available for pancreatic cancer patients?

Cadonilimab is currently in Phase II development. If Phase III trials are successful, the drug could potentially reach market in 3-5 years, though Akeso has not announced specific timelines for advancing to pivotal trials or regulatory submissions.

How significant are these results for pancreatic cancer treatment?

These results are potentially significant given pancreatic cancer’s poor prognosis and historical resistance to immunotherapy. However, the magnitude of benefit hasn’t been fully disclosed, and Phase II results don’t always translate to Phase III success, particularly in this challenging cancer type.